Epidermal growth factor

Team from Korea University Medicine Explores Ways to Overcome Cisplatin Resistance and Alleviate Pain in Cancer Treatment

Retrieved on: 
Friday, July 21, 2023

SEOUL, South Korea, July 21, 2023 /PRNewswire/ -- Cisplatin is a widely used chemotherapy drug for various types of cancers. However, frequent usage can lead to the development of drug resistance and neuropathic pain, eventually resulting in treatment failure. In a new study, researchers from South Korea investigated the underlying pathways contributing to this resistance and identified potential therapeutic targets that can be modulated to overcome this. By understanding and targeting these mechanisms, effective treatment strategies can be developed and implemented.

Key Points: 
  • However, frequent usage can lead to the development of drug resistance and neuropathic pain, eventually resulting in treatment failure.
  • But the continued use of cisplatin can lead to the development of cisplatin resistance and other side effects, like chemotherapy-induced neuropathic pain.
  • Now, in a new study, Prof. Tae Woo Kim from Korea University Medicine and his team have explored the pathways leading to cisplatin resistance.
  • This study serves as valuable proof-of-concept for TRPV1 as a therapeutic target to combat cisplatin resistance and neuropathic pain, thereby improving the outlook for patients with cervical cancer.

Bioasis Provides Corporate Update and Announces Suspension of Operations

Retrieved on: 
Tuesday, June 20, 2023

In pursuing these transactions, Bioasis was assisted by third party advisors, including Shadow Lake Group and Maxim Group.

Key Points: 
  • In pursuing these transactions, Bioasis was assisted by third party advisors, including Shadow Lake Group and Maxim Group.
  • The current economic environment and market conditions for small-cap development stage biopharmaceutical companies continue to be very challenging.
  • As a result, the board of directors has made the difficult decision to suspend all of Bioasis’ operations.
  • On behalf of the Board of Directors of Bioasis Technologies Inc.

Bioasis Provides Update on Business Operations

Retrieved on: 
Thursday, March 23, 2023

NEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need provides this update on its business operations.

Key Points: 
  • NEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need provides this update on its business operations.
  • The Company continues to reduce its research activities and defer payments to its vendors and officers in order to extend its cash while it seeks strategic alternatives to finance its operations.
  • Bioasis continues to explore and evaluate strategic alternatives to enhance shareholder value, including continuing as a standalone company and evaluating potential strategic transactions or partnerships as well as any financing alternatives that may be available.
  • On behalf of the Board of Directors of Bioasis Technologies Inc.

Bioasis Announces AGM Results and Provides Update on Financial Position

Retrieved on: 
Friday, February 3, 2023

Shareholders also approved the re-appointment of Manning Elliott LLP as auditors of the Company for the ensuing year.

Key Points: 
  • Shareholders also approved the re-appointment of Manning Elliott LLP as auditors of the Company for the ensuing year.
  • Bioasis also wishes to update shareholders on its current financial condition.
  • Midatech has subsequently advised Bioasis that it is currently unable to make the expense reimbursement payment as a result of its own liquidity constraints.
  • Bioasis currently expects that its remaining cash reserves will allow it to continue operations only until approximately March 2023.

Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc

Retrieved on: 
Monday, January 23, 2023

The Arrangement Agreement provided for Midatech’s acquisition of all of Bioasis’ issued and outstanding shares in exchange for ordinary shares of Midatech by way of a statutory plan of arrangement under the laws of British Columbia (the “Arrangement”).

Key Points: 
  • The Arrangement Agreement provided for Midatech’s acquisition of all of Bioasis’ issued and outstanding shares in exchange for ordinary shares of Midatech by way of a statutory plan of arrangement under the laws of British Columbia (the “Arrangement”).
  • Midatech has announced that its shareholders did not approve the Arrangement at the general meeting of Midatech shareholders held earlier today.
  • As a result, the Arrangement cannot proceed and Bioasis has provided written notice to Midatech that it has exercised its right to terminate the Arrangement Agreement.
  • Under the terms of the Arrangement Agreement, Midatech is required to make an expense reimbursement payment to Bioasis of US$225,000.

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022

Retrieved on: 
Thursday, January 19, 2023

NEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC .

Key Points: 
  • NEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC .
  • (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended November 30, 2022.
  • All are available under the Company’s profile on SEDAR and on the Company’s website at www.bioasis.us/investors/ .
  • On behalf of the Board of Directors of Bioasis Technologies Inc.

Bioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of Securityholders

Retrieved on: 
Wednesday, January 11, 2023

The Meeting is scheduled to be held virtually at meetnow.global/MUTHYPM on February 3, 2023 at 1:00 p.m. (Vancouver time).

Key Points: 
  • The Meeting is scheduled to be held virtually at meetnow.global/MUTHYPM on February 3, 2023 at 1:00 p.m. (Vancouver time).
  • Bioasis securityholders of record as of the close of business on December 30, 2022, are entitled to receive notice of and vote at the Meeting.
  • The Board unanimously recommends that Bioasis securityholders vote in favour of the Arrangement.
  • Bioasis securityholders are urged to read the Circular and its appendices carefully and in their entirety.

Florida Cancer Specialists & Research Institute Contributing to Rapid Advancements in Breast Cancer Treatment

Retrieved on: 
Tuesday, December 13, 2022

Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) hematologists and medical oncologists were contributors to several presentations at the San Antonio Breast Cancer Symposium® (SABCS) this past week, sharing the findings of state-of-the-art breast cancer research conducted at FCS.

Key Points: 
  • Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) hematologists and medical oncologists were contributors to several presentations at the San Antonio Breast Cancer Symposium® (SABCS) this past week, sharing the findings of state-of-the-art breast cancer research conducted at FCS.
  • Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • Over the past 5 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.
  • Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies, and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy.

Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

Retrieved on: 
Thursday, June 16, 2022

NEW HAVEN, Conn., U.S.A., June 16, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”) a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced today that it has entered into an asset purchase agreement with the owners (the “Sellers”) of Cresence AS of Oslo, Norway.

Key Points: 
  • This transaction is transformational for Bioasis, bringing Phase 2 ready assets aligned with our focus in rare disease and orphan drug indications.
  • The transfer of these assets to Bioasis will speed up the development of EGF therapeutics for the treatment of certain rare neurodegenerative disorders, Professor Francois Curtin, co-founder and Vice-Chairman of the Cresence Board observed.
  • In addition, the combination of Bioasis xB3TM platform with our EGF technology is anticipated to improve the brain delivery of our neurotherapeutic molecules, he added.
  • The addition of this key intellectual property provides Bioasis a Phase 2 clinical stage ready molecule that is synergistic with Bioasis existing technology and therapeutic areas of interest.

Neuvivo's NP001 - an Immune System Regulator - Has Effect on Biomarkers of Microbial Translocation in ALS Patients Responsive to Treatment

Retrieved on: 
Thursday, June 2, 2022

PALO ALTO, Calif. and EDINBURGH, Scotland, June 2, 2022 /PRNewswire/ -- Today, at the ENCALS Conference (European Network to Cure ALS) Neuvivo presented an abstract titled: "Plasma biomarkers of microbial translocation are modulated in ALS patients clinically responsive to NP001".

Key Points: 
  • PALO ALTO, Calif. and EDINBURGH, Scotland, June 2, 2022 /PRNewswire/ -- Today, at the ENCALS Conference (European Network to Cure ALS) Neuvivo presented an abstract titled: "Plasma biomarkers of microbial translocation are modulated in ALS patients clinically responsive to NP001".
  • This is a process known to occur in patients with ALS and other neurodegenerative diseases.
  • In phase 2 studies with NP001 in ALS patients, clinical signs of disease activity and respiratory vital capacity were positively affected compared to controls.
  • "NP001 treatment reduced inflammation and importantly, enhanced production of wound healing factors," said Michael McGrath, MD, PhD, Chief Scientific Officer, Neuvivo.